#202 Dementia Part 2: Gray Matters Segment
About this episode
This episode discusses the effectiveness of dementia medications and when to consider deprescribing them.
Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help . In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them. • Do cholinesterase inhibitors really work? • What should clinicians know about lecanemab and donanemab before referring patients? • How much benefit should we expect and for how long? • When should you deprescribe dementia medications ? 🔹 Sponsor: Caraway’s cookware set is a favorite for a reason. For 10% off, go to Carawayhome.com/ CoreIM or use code CoreIM at checkout. 🔹 Transcript and Shownotes 02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia? 09:41 | Deep Dive 2: Prescribing medications for cognitive decline 29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline 35:46 | Deep Dive 4: Planning for an uncertain future Tags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistant Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out Branch Basics and use my code…
Sponsors
Caraway
More episodes of Core IM | Internal Medicine Podcast
- #205 Nutrition Studies, Coffee and the CRAVE Trial: Beyond Journal Club with the NEJM Group
- #204 Diabetic Foot Infections & Osteomyelitis: 5 Pearls Segment
- #203 POCUS for AKI & Dialysis | Real Cases That Changed Management
- #201: Dementia Part 1: Gray Matters Segment
- #200: Insulin and QWINT-1 Trial in T2DM: Beyond Journal Club Segment with NEJM Group
- #199 Privacy & Confidentiality: At the Bedside Segment
Explore listener stats, chart rankings, contacts and more on the Core IM | Internal Medicine Podcast podcast page.